chronic lymphocytic leukemia
AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.
AbbVie investors were relieved when the company announced first-quarter results that exceeded forecasts, driven largely by an increase in Humira sales.
Analysts have pegged AbbVie’s leukemia newcomer Venclexta (venetoclax) as a future blockbuster. But unless something changes, England won’t be helping the med get there.